A few months after a key label expansion, AstraZeneca’s asthma treatment Fasenra has received FDA approval to treat a rare ...

Keytruda is already approved in more than 40 different oncology indications, but its latest label expansion is a first for ...

Novo Nordisk is doubling down on its investment in genetic medicine-based biotechs, inking a new collaboration with a lipid ...

Roivant is once again reaping the benefits of its bespoke business model. This time, it's selling Dermavant to Organon for up ...

Insilico Medicine reported Phase 2a results for its lead program, saying the study achieved its primary endpoint of safety ...

A startup in Brazil that lets people easily buy medicine online by combining a consumer-friendly experience with prescription ...

Novartis was already riding a wave of momentum with Kisqali, and now it has a new FDA nod to break into the early breast ...

The FDA on Tuesday firmed up its position that in some limited circumstances, clinical trial data may be obtained from ...

Merck and Daiichi Sankyo have passed a Phase 3 with the lead antibody-drug conjugate from the megadeal they disclosed at last ...

Plus, news about Vigil Neuroscience, AC Immune and Athira Pharma: Capricor Therapeutics, Nippon Shinyaku expand commercial pact into Europe: The new deal builds off an existing partnership for a ...

In early 2023, the founder of the psychedelic medicine company Lykos Therapeutics met with a potential investor for dinner, ...

Cigna, the owner of one of the top pharmacy benefit managers, is suing the Federal Trade Commission and Commissioner Lina ...